F8 and hyperinsulinemic hypoglycemia, familial, 4: Subcutaneous (SC) emicizumab therapy for FVIII deficiency with and without inhibitors has been licenced by the FDA,32 which will offer a degree of freedom from fluctuating factor levels by conferring a constant level of protection while also removing the burden of IV infusion.33, 34 The level of protection conferred appears to be in the range which will prevent most bleeds, but does not confer a normal or near‐normal level of protection, so treatment for breakthrough bleeds and surgery with FVIII clotting factor will continue to be required.